PhaseV
PhaseV, founded in the early 2020s and headquartered in Boston, specializes in AI/ML-driven solutions for optimizing clinical trials.
Profile
PhaseV uses AI and machine learning to optimize clinical trial design and execution, reducing costs and improving success rates.
PhaseV, founded in the early 2020s and headquartered in Boston, specializes in AI/ML-driven solutions for optimizing clinical trials. The company has rapidly gained traction in the biopharma sector, leveraging its proprietary AI platform to enhance trial design, execution, and outcomes. PhaseV's platform integrates a robust data lake with over two million patient-level records, enabling predictive modeling across more than 20 therapeutic areas.
The company's solutions have demonstrated significant ROI, reducing trial costs by up to 50%, shortening trial durations by 40%, and increasing the probability of trial success by over 30%. In May 2025, PhaseV secured a $50 million Series A funding round led by Accel and Insight Partners, bringing its total funding to $65 million. This capital infusion has fueled its expansion, with the company now serving over 40 global sponsors, including seven of the world's top pharmaceutical companies. PhaseV has earned industry recognition, including being named to CB Insights' Digital Health 50 list and TechCrunch's AI Disruptors 60 list, and was honored as BioTech Breakthrough's 'Analytics Solution of the Year' in 2025.
Who buys this
- Pharmaceutical companies
- Biotech firms
- Contract research organizations (CROs)
- Clinical trial sponsors
- Healthcare research institutions
Strengths and what to watch
Strengths
- Proprietary AI platform integrated with over two million patient-level records
- Demonstrated ROI with up to 50% reduction in trial costs and 40% shorter trial durations
- Trusted by over 40 global sponsors, including seven top pharmaceutical companies
Watch for
- Dependence on a few large pharmaceutical clients for revenue
- Potential challenges in scaling AI solutions across diverse therapeutic areas
- Regulatory scrutiny around AI-driven clinical trial methodologies
Recent moves
Key Information
- Founded
- 2020
- Headquarters
- Boston
Frequently Asked Questions
What does PhaseV do?
PhaseV uses AI and machine learning to optimize clinical trial design and execution. Their platform reduces trial costs by up to 50%, shortens durations by 40%, and improves success rates by 30% through predictive modeling across 20+ therapeutic areas using 2M+ patient records.
How does PhaseV's AI improve clinical trials?
PhaseV's proprietary AI analyzes over two million patient records to optimize trial design, site selection, and patient recruitment. This reduces costs by 50%, accelerates timelines by 40%, and increases trial success probability by 30% compared to traditional methods.
Which companies use PhaseV's technology?
PhaseV serves over 40 global sponsors, including seven top pharmaceutical companies. Their clients span pharmaceutical firms, biotechs, contract research organizations (CROs), and healthcare research institutions seeking AI-driven clinical trial optimization.
How much funding has PhaseV raised?
PhaseV secured $50 million in Series A funding in May 2025, led by Accel and Insight Partners, bringing total funding to $65 million. This capital supports platform development and expansion across therapeutic areas.
What awards has PhaseV won?
PhaseV earned BioTech Breakthrough's 'Analytics Solution of the Year' (2025), made CB Insights' Digital Health 50 list, and was named to TechCrunch's AI Disruptors 60 list. These recognize its AI platform's impact on clinical trial efficiency.
What are PhaseV's clinical trial success rates?
PhaseV's AI platform demonstrates 30% higher trial success probabilities compared to conventional methods. This stems from optimized design, predictive analytics using 2M+ patient records, and real-time adjustments during trial execution across 20+ therapeutic areas.
Sources
- www.prnewswire.com — $50M Series A funding round
- www.prnewswire.com — Record growth and milestones in 2025
- www.prnewswire.com — Industry awards and recognition
- www.prnewswire.com — AI-driven site selection and real-time analytics